Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 1,045.3% in May

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 330,345 shares, a growth of 1,045.3% from the May 14th total of 28,844 shares. Based on an average trading volume of 3,203,228 shares, the days-to-cover ratio is presently 0.1 days. Currently, 21.2% of the company’s shares are short sold.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Price Performance

Shares of Aethlon Medical stock traded down $0.09 during trading on Tuesday, reaching $1.94. 135,568 shares of the company traded hands, compared to its average volume of 1,627,829. The firm has a market capitalization of $3.05 million, a PE ratio of -0.13 and a beta of 1.49. The company has a 50 day moving average price of $2.23 and a 200-day moving average price of $2.51. Aethlon Medical has a 1-year low of $1.36 and a 1-year high of $27.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.